Discovery of Highly Potent and Selective Small Molecule ADAMTS-5 Inhibitors That Inhibit Human Cartilage Degradation via Encoded Library Technology (ELT)

DOI Web Site 2 Citations
  • Hongfeng Deng
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Heather O’Keefe
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Christopher P. Davie
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Kenneth E. Lind
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Raksha A. Acharya
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • G. Joseph Franklin
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Jonathan Larkin
    Biopharm Discovery, Medicines Discovery and Development, GlaxoSmithKline, Upper Merion, Pennsylvania, United States
  • Rosalie Matico
    Biological Reagent and Assay Development, Platform Technology and Science, GlaxoSmithKline, Upper Providence, Pennsylvania, United States
  • Michael Neeb
    Center of Excellence for External Drug Discovery, Medicines Discovery and Development, GlaxoSmithKline, Upper Merion, Pennsylvania, United States
  • Monique M. Thompson
    Biological Reagent and Assay Development, Platform Technology and Science, GlaxoSmithKline, Upper Providence, Pennsylvania, United States
  • Thomas Lohr
    Biopharm Discovery, Medicines Discovery and Development, GlaxoSmithKline, Upper Merion, Pennsylvania, United States
  • Jeffrey W. Gross
    Screening and Compound Profiling, Platform Technology and Science, GlaxoSmithKline, Upper Providence, Pennsylvania, United States
  • Paolo A. Centrella
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Gary K. O’Donovan
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Katie L. (Sargent) Bedard
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Kurt van Vloten
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Sibongile Mataruse
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Steven R. Skinner
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Svetlana L. Belyanskaya
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Tiffany Y. Carpenter
    Muscle Metabolism Discovery Performance Unit, Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, North Carolina, United States
  • Todd W. Shearer
    Muscle Metabolism Discovery Performance Unit, Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, North Carolina, United States
  • Matthew A. Clark
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • John W. Cuozzo
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Christopher C. Arico-Muendel
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
  • Barry A. Morgan
    ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States

Journal

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top